LYON, France & PHILADELPHIA--(BUSINESS WIRE)--ERYtech Pharma announces that it has started a phase II clinical trial with GRASPA® as first-line treatment among patients with acute lymphoblastic leukaemia (ALL) aged 55 and older. A first cohort of 3 patients has already been recruited.
